The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Real-world outcomes of esophagectomy versus chemoradiotherapy for clinical stage I esophageal squamous cell carcinoma.
 
Hiroki Yukami
No Relationships to Disclose
 
Kentaro Sawada
No Relationships to Disclose
 
Hisashi Fujiwara
No Relationships to Disclose
 
Saori Mishima
No Relationships to Disclose
 
Daisuke Kotani
Honoraria - Chugai Pharma; Lilly Japan; Merck Serono; Ono Pharmaceutical; Sysmex; Taiho Pharmaceutical; Takeda
 
Tomohiro Kadota
No Relationships to Disclose
 
Atsushi Inaba
No Relationships to Disclose
 
Keiichiro Nishihara
No Relationships to Disclose
 
Daiki Sato
No Relationships to Disclose
 
Keiichiro Nakajo
No Relationships to Disclose
 
Yusuke Yoda
No Relationships to Disclose
 
Masaki Nakamura
Honoraria - AstraZeneca
Consulting or Advisory Role - MSD
 
Hidehiro Hojo
No Relationships to Disclose
 
Tomonori Yano
Honoraria - AstraZeneca; Eisai; Olympus
Speakers' Bureau - Meiji Seika Kaisha; Olympus
Research Funding - HOYA Techonosurgical (Inst); Rakuten Medical (Inst)
 
Takeo Fujita
No Relationships to Disclose
 
Takashi Kojima
Honoraria - Oncolys BioPharma; Ono Pharmaceutical
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; Merck; MSD; Ono Pharmaceutical
Research Funding - Astellas Amgen BioPharama (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst)